Genprex varieties Medical Advisory Board to assist its oncology and diabetes improvement packages

0
447

The CAB will lead and advise Genprex as it advances its REQORSA immunogen therapy program, including its Acclaim clinical trials in non-small cell lung cancer, and its pre-clinical diabetes gene therapy program

Genprex Inc () announced Monday the formation of a Clinical Advisory Board (CAB) to support its oncology and diabetes development programs.

The company, made up of outstanding clinical specialists, said the CAB will lead and advise Genprex in advancing its REQORSA immunogen therapy program, including its Acclaim clinical trials in non-small cell lung cancer, and its pre-clinical diabetes gene therapy program. Some of the members also have additional functions in the company.

READ: Genprex full steam ahead toward non-small cell lung cancer studies in 2021

“We are excited to bring this group of experienced physicians in the fields of oncology and diabetes together to support and advise Genprex as we advance our clinical development programs,” said Rodney Varner, CEO of Genprex, in a statement.

“The Clinical Advisory Board’s experience in clinical trials of cancer and diabetes therapies, combined with its expertise in advising small and large biotechnology companies, is invaluable as our drug candidates advance into the clinic.”

Genprex Clinical Advisory Board members include:

Dr. Michael Morse, Professor of Medicine in the Department of Medical Oncology and Professor in the Department of Surgery at Duke University Medical Center. His clinical expertise includes the treatment of gastrointestinal malignancies such as colon, liver, gastro-esophageal and pancreatic cancers. His research expertise includes the development of targeted therapies including immunotherapies for cancer. He is the editor for Current Opinions in Biologic Therapies and has been the lead researcher in a number of research-initiated and industry-supported Phase 1 and 2 clinical trials of cancer immunotherapy and therapies for gastrointestinal malignancies.

Col George E. Peoples, MD, served 30 years of active service as a surgeon and scientist in the military. He is the founder and director of the Cancer Vaccine Development Program (CVDP), which has focused on the discovery, development and clinical evaluation of cancer vaccines for more than 20 years. Four of the program’s cancer vaccines have been approved for commercial development. Dr. Peoples is currently the CEO of Cancer Insight LLC, the commercial counterpart of CVDP, a boutique cancer immunotherapy contract research organization that conducts multiple Phase 1 and 2 clinical trials. He is also Professor of Surgery at the Uniformed Services University of Health Sciences and Professor (adjunct) of Surgical Oncology at the MD Anderson Cancer Center (MDACC).

Dr. Andrew Becker is President and Founder of Becker Pharmaceutical Consulting, a market research, competitive intelligence and strategic planning consultancy that provides analysis and strategy services to companies ranging from small biotechnology and medical device companies to large multinational pharmaceutical companies on a global basis. He received both his medical degree and PhD in molecular pharmacology from Stanford University, where his research focused on signaling pathways for the insulin and IGF-1 receptors, deciphering the structure and function of the insulin-degrading enzyme and its role in insulin processing .

Dr. William Gannon, Jr. is the Vice President of Regulatory Affairs at Genprex. He is responsible for managing the company’s regulatory affairs for the upcoming clinical trials. He will also act as a medical monitor liaising with medical staff at the trial sites and supporting communications with the U.S. Food and Drug Administration throughout the clinical trials.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham